Skip to main content
logo
SAB Biotherapeutics, Inc. (SABS)
NASDAQ: SABS · Real-Time Price · USD
3.790
+0.220 (6.16%)
At close: Aug 3, 2026, 4:00 PM EDT
3.840
+0.050 (1.32%)
After-hours: Aug 3, 2026, 4:56 PM EDT

SAB Biotherapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
--1.322.2423.960.88
Revenue Growth
---40.94%-90.63%-60.73%10.21%
Gross Profit
--1.322.2423.960.88
Selling, General & Admin
18.0914.613.9823.816.3817.09
Research & Development
40.0934.3530.2516.5236.4457.18
Total Operating Expenses
58.1848.9544.2340.3152.8274.27
Operating Income
-58.18-48.95-42.91-38.08-28.92-13.39
Interest Income
2.421.431.290.580.070.02
Interest Expense
-0.23-0.24-0.32-0.32-0.3-0.29
Other Non-Operating Income (Expense)
55.661.047.84-4.3910.43-3.48
Total Non-Operating Income (Expense)
57.7862.238.81-4.1210.2-3.75
Pretax Income
-0.413.27-34.11-42.19-18.72-17.14
Provision for Income Taxes
-----0.03-
Net Income
-0.413.27-34.11-42.19-18.69-17.14
Net Income to Common
-0.413.27-34.11-42.19-18.74-17.14
Net Income Growth
------
Shares Outstanding (Basic)
30199643
Shares Outstanding (Diluted)
74619643
Shares Change
695.66%562.28%67.74%26.86%59.20%1.21%
EPS (Basic)
-1.450.22-3.68-7.64-4.31-6.30
EPS (Diluted)
-2.11-0.79-3.68-7.64-4.31-6.30
EPS Growth
------
Free Cash Flow
-51.25-45.71-34.63-25.32-25.63-8.96
Free Cash Flow Growth
------
Free Cash Flow Per Share
-0.69-0.75-3.74-4.59-5.89-3.28
Gross Margin
--100.00%100.00%100.00%100.00%
Operating Margin
---3244.87%-1700.56%-120.97%-22.00%
Profit Margin
---2579.03%-1884.50%-78.19%-28.16%
FCF Margin
---2618.65%-1130.71%-107.20%-14.71%
EBITDA
-55.12-45.87-38.12-34.33-25.63-11.74
EBITDA Margin
---2882.46%-1533.28%-107.20%-19.28%
EBIT
-58.18-48.95-42.91-38.08-28.92-13.39
EBIT Margin
---3244.87%-1700.56%-120.97%-22.00%
Effective Tax Rate
-0.00%0.00%0.00%0.14%0.00%
SEC Filings: 10-K · 10-Q